

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

## Patient: Patient, Example

4/12/1982
Male
01234567890ABCD, 012345
01234567890ABCD
00/00/0000 00:00

## Ganglioside (GM1, GD1b, and GQ1b) Antibodies, IgG and IgM

ARUP test code 2004998

GM1 Antibody, IgG	7 IV	(Ref Interval: 0-50)
GM1 Antibody, IgM		(Ref Interval: 0-50) ATION: Ganglioside (GM1) Antibodies, IgG and IgM
	29 IV or less: Neg 30-50 IV: Equivoca 51-100 IV: Positiv 101 IV or greater:	1 e
	neuropathies. Eleva acid (GM1) are asso neuropathies, parti may occur as IgM (p These antibodies ma connective tissue d tests by themselves conjunction with ot This test was devel determined by ARUP approved by the US	ies are associated with diverse peripheral ted antibody levels to ganglioside-monosialic ciated with motor or sensorimotor cularly multifocal motor neuropathy. Anti-GM1 olyclonal or monoclonal) or IgG antibodies. y also be found in patients with diverse iseases as well as normal individuals. These are not diagnostic and should be used in her clinical parameters to confirm disease. oped and its performance characteristics Laboratories. It has not been cleared or Food and Drug Administration. This test was certified laboratory and is intended for
GD1b Antibody, IgG	305 IV H	(Ref Interval: 0-50)
GD1b Antibody, IgM	59 IV Н	(Ref Interval: 0-50)
GQ1b Antibody, IgG	312 IV H	(Ref Interval: 0-50)
GQ1b Antibody, IgM	76 IV H	(Ref Interval: 0-50)

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:



INTERPRETIVE INFORMATION: Ganglioside (GD1b and GQ1b) Antibodies, IgG and IgM

29 IV or less: Negative 30-50 IV: Equivocal 51-100 IV: Positive 101 IV or greater: Strong positive

Ganglioside antibodies are associated with diverse peripheral neuropathies. GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. GQ1b antibodies are seen in more than 80% of patients with Miller-Fisher syndrome and may be elevated in Guillain-Barre syndrome patients with ophthalmoplegia. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES						
Procedure	Accession	Collected	Received	Verified/Reported		
GM1 Antibody, IgG	24-015-400921	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		
GM1 Antibody, IgM	24-015-400921	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		
GD1b Antibody, IgG	24-015-400921	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		
GD1b Antibody, IgM	24-015-400921	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		
GQ1b Antibody, IgG	24-015-400921	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		
GQ1b Antibody, IgM	24-015-400921	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		

## END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 24-015-400921 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 2 | Printed: 2/2/2024 11:30:29 AM 4848